Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649174 | 0.91 | TSHR (0.42) | SIGMAR1MCHR1TSHRALDH1A1LMNA | |
| SCHEMBL4650499 | 0.85 | KMT2A (0.51) | DRD2DRD4 | |
| SCHEMBL4649360 | 0.81 | SIGMAR1 (0.48) | SIGMAR1MCHR1TSHRALDH1A1LMNA | |
| SCHEMBL4649247 | 0.79 | SIGMAR1 (0.44) | SIGMAR1MCHR1TSHRALDH1A1LMNA | |
| SCHEMBL4648634 | 0.79 | CHRM2 (0.40) | DRD2KCNH2 | |
| SCHEMBL4803652 | 0.77 | PTPN1 (0.42) | SIGMAR1MCHR1TSHRALDH1A1LMNA | |
| SCHEMBL13074367 | 0.77 | MEN1 (0.59) | TSHRALDH1A1LMNAFAAH | |
| SCHEMBL13037186 | 0.77 | MEN1 (0.59) | TSHRALDH1A1LMNAFAAH | |
| SCHEMBL4649730 | 0.72 | NAMPT (0.42) | SIGMAR1TSHRALDH1A1 | |
| SCHEMBL14002084 | 0.69 | SIGMAR1 (0.57) | SIGMAR1DRD2DRD4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | claimed |
| EP-1904495-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007281-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | SIGMAR1 366/4885MCHR1 79/4885TSHR 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.